Abstract:Abstract Background Inflammatory bowel disease (IBD) patients may experience a suboptimal response to anti-tumour necrosis factor (TNF) therapy. In China, these data are limited. The EXPLORE study aimed to assess the incidence and indicators of suboptimal response to first-line anti-TNF agents in IBD patients in real-world practice in the newly industrialised countries. Methods The EXPLORE study was a multinational, retrospective chart review study. In the China subgroup, adult patients from 10 centres diagnosed with ulcerative colitis (UC) or Crohn’s disease (CD) and who initiated first anti-TNF treatment between March 2010 and March 2015, were included. The cumulative incidence (CI) of suboptimal response was assessed over 24 months since the anti-TNF initiation. The indicators of suboptimal response included: IBD-related hospitalisation, dose-escalation, discontinuation including switch to another anti-TNF, non-biologic therapy augmentation, or IBD-related surgery. Primary non-response (PNR) and secondary loss of response (SLOR) were defined as any suboptimal response indicator at <4 and ≥4 months after anti-TNF initiation, respectively. Results Overall, 287 first-line anti-TNF treated patients (35 UC; 252 CD) were included: male, UC 54.3% (n = 19), CD 74.6% (n = 188); mean (SD) age (years), UC 43.1 (14.2), CD 31.9 (11.3); median (min-max) disease duration (years), UC 1.0 (0–9), CD <1 year (0–21); median (min-max) follow-up (months), UC 27.6 (24–60), CD 40.0 (24–60). At 12 and 24 months, the CI of suboptimal response to first anti-TNF treatment was 51.4% and 75.7% in UC, 45.4% and 57.0% in CD, respectively (Figure 1). The median time to the first suboptimal response was 7.2 months in UC and 14.3 months in CD. The CI of PNR was 31.2% in UC and 33.7% in CD. The CI of SLOR was 29.4% and 64.7% in UC, 17.7% and 35.2% in CD at 12 and 24 months, respectively. The most frequent first suboptimal response indicator was ‘discontinuation of anti-TNF therapy’ in UC patients (56.3%) while for CD patients it was ‘IBD-related hospitalisation’ (56.1%) followed by ‘augmentation with non-biological therapy’ in both cohorts (UC 31.3%; CD 22.8%). Conclusion Approximately three-quarters of UC and over half of CD patients experienced a suboptimal response to their first anti-TNF agent at 24 months. Given the high unmet needs observed with anti-TNF therapies in China, IBD patients may benefit from greater optimisation of care and new biologic options.

Temporal Changes in the Treatment Paradigm and Long-term Prognosis of Patients With Crohn's Disease: A Hospital-Based Cohort Study in China

P479 Trends in Medication Use and Treatment Patterns in Chinese Patients with Inflammatory Bowel Diseases: A Multicenter Cohort Study from 1999 to 2020

Temporal trends in surgery for Crohn’s disease: A ten-year single-center retrospective study

Trends in medication use and treatment patterns in Chinese patients with inflammatory bowel disease

Treatment Decision-making in Chinese Inflammatory Bowel Disease Patients

Indicators of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy in Patients from China with Inflammatory Bowel Disease: Results from the EXPLORE Study

P574 Incidence and Indicators of Suboptimal Response to Tumour Necrosis Factor Antagonist Therapy in Chinese Patients with Inflammatory Bowel Disease: Results from the EXPLORE Study

Characterization of Clinical and Serologic Features of Crohnʼs Disease and Anti-TNFα Use in a Chinese Cohort

IDDF2020-ABS-0170 the Clinical Characteristics and Outcomes of Crohn’s Disease Patients with Perianal Disease Onset at Pediatric Versus Adult: a 10-Year Observational Study

Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions Through Balancing Abnormal Immune Response in Gut Mucosa

Prophylactic Antitubercular Therapy Is Associated With Accelerated Disease Progression in Patients With Crohn's Disease Receiving Anti-TNF Therapy: A Retrospective Multicenter Study

Infliximab For The Treatment Of Crohn'S Disease: Efficacy And Safety In A Chinese Single-Center Retrospective Study

Current diagnosis and management of Crohn’s disease in China: results from a multicenter prospective disease registry

Risk Factors of Patients with Disabling Crohn's Disease in China

Changes in Clinical Features and Seasonal Variations of Crohn’s Disease at Diagnosis: a 10-Year Observational Study in China

Improvements in the Long-Term Outcome of Crohn’s Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort

P430 Long-term Outcome of Crohn's Disease Patients Treated with Infliximab

P416 Turning Point: Declining surgery rates and predictors for surgery in a three-year prospective inception cohort of Crohn's Disease in China

P431 Long-term Efficacy of Maintenance Therapy with Thiopurines in Crohn's Disease

Infliximab for the Treatment of Crohn’s Disease